Dual-ligand modified polymer-lipid hybrid nanoparticles for docetaxel targeting delivery to Her2/neu overexpressed human breast cancer cells

Journal of Biomedical Nanotechnology

Volumn 11, Issue 8, 2015, Pages 1401-1417

  Yang, Zhe ^a   Tang, Wenxin ^b   Luo, Xingen ^a   Zhang, Xiaofang ^a   Zhang, Chao ^a   Li, Hao ^a   Gao, Di ^a   Luo, Huiyan ^a,c   Jiang, Qing ^a   Liu, Jie ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Anti HER2 neu Peptide Mimic; Breast Cancer; Dual Ligand; Endocytic Pathway; Hybrid Nanoparticles; Modified HIV 1 Tat

Indexed keywords

CELLS; CYTOLOGY; DISEASES; DRUG PRODUCTS; HYBRID VEHICLES; LIGANDS; MOLECULAR BIOLOGY; NANOPARTICLES; PEPTIDES;

BREAST CANCER; ENDOCYTIC PATHWAYS; HIV-1 TAT; HYBRID NANOPARTICLE; PEPTIDE MIMICS;

TARGETED DRUG DELIVERY;

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPID; MACROGOL; NANOCARRIER; POLYGLACTIN; TRANSACTIVATOR PROTEIN; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; LIGAND; NANOCAPSULE; POLYMER; TAXOID;

ARTICLE; BREAST CANCER CELL LINE; CAVEOLA; CONTROLLED STUDY; DENSITY; DRUG POTENCY; ENDOCYTOSIS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; INTERNALIZATION; INTRACELLULAR TRANSPORT; LIPID MONOLAYER; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; NANOPHARMACEUTICS; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; BREAST NEOPLASMS; CHEMISTRY; DIFFUSION; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIFFUSION; HUMANS; LIGANDS; LIPIDS; NANOCAPSULES; POLYMERS; RECEPTOR, ERBB-2; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TAXOIDS; TREATMENT OUTCOME;

EID: 84931457203     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2086     Document Type: Article

References (51)

1. B. Lu, S.-B. Xiong, H. Yang, X.-D. Yin, and R.-B. Chao, Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur. J. Pharm. Sci. 28, 86 (2006).
2. F. Danhier, O. Feron, and V. Preat, To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148, 135 (2010).
3. K. H. Min, K. Park, Y. S. Kim, S. M. Bae, S. Lee, H. G. Jo, R. W. Park, I. S. Kim, S. Y. Jeong, K. Kim, and I. C. Kwon, Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release 127, 208 (2008).
4. G. Zhang, X. Zeng, and P. Li, Nanomaterials in cancer-therapy drug delivery system. J. Biomed. Nanotech. 9, 741 (2013).
5. L. M. Zhang, J. G. Xia, Q. H. Zhao, L. W. Liu, and Z. J. Zhang, Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small 6, 537 (2010).
6. W. Tai, R. Mahato, and K. Cheng, The role of HER2 in cancer therapy and targeted drug delivery. J. Control. Release 146, 264 (2010).
7. V. Guillemard, H. N. Nedev, A. Berezov, R. Murali, and H. U. Saragovi, Her2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell. Biol. 24, 351 (2005).
8. S. Girish, M. Gupta, B. Wang, D. Lu, I. E. Krop, C. L. Vogel, H. A. B. Iii, P. M. LoRusso, J.-H. Yi, O. Saad, B. Tong, Y.-W. Chu, S. Holden, and A. Joshi, Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 69, 1229 (2012).
9. Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, and R. K. Jain, Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416, 279 (2002).
10. X. Liu, K. Nakamura, Y. Wang, D. Cheng, M. Liang, N. Xiao, L. Chen, M. Rusckowski, and D. J. Hnatowich, Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle. J. Biomed. Nanotech. 6, 153 (2010).
11. I. Steinhauser, B. Spänkuch, K. Strebhardt, and K. Langer, Trastuzumab-modified nanoparticles: Optimisation of preparation and uptake in cancer cells. Biomaterials 27, 4975 ( 2006).
12. M. Tan, Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 66, 3764 (2006).
13. C. Widakowich, G. de Castro, E. de Azambuja, P. Dinh, and A. Awada, Review: Side effects of approved molecular targeted therapies in solid cancers. Oncologist 12, 1443 (2007).
14. B.-W. Park, H.-T. Zhang, C. Wu, A. Berezov, X. Zhang, R. Dua, Q. Wang, G. Kao, D. M. O'Rourke, and M. I. Greene, Rationally designed anti-her2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18, 194 (2000).
15. G. Kibria, H. Hatakeyama, N. Ohga, K. Hida, and H. Harashima, Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J. Control. Release 153, 141 (2011).
16. D. R. Elias, A. Poloukhtine, V. Popik, and A. Tsourkas, Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomed. Nanotechnol. Biol. Med. 9, 194 ( 2013).
17. Z. Yang, X. Luo, X. Zhang, J. Liu, and Q. Jiang, Targeted delivery of 10-hydroxycamptothecin to human breast cancers by cyclic RGD-modified lipid-polymer hybrid nanoparticles. Biomed. Mater. 8, 025012 (2013).
18. C. J. Cheng and W. M. Saltzman, Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cellpenetrating peptides. Biomaterials 32, 6194 ( 2011).
19. J. C. M. Stewart, Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104, 10 (1980).
20. T. K. Endres, M. Beck-Broichsitter, O. Samsonova, T. Renette, and T. H. Kissel, Self-assembled biodegradable amphiphilic PEG-PCLlPEI triblock copolymers at the borderline between micelles and nanoparticles designed for drug and gene delivery. Biomaterials 32, 7721 (2011).
21. Y. Cu and W. M. Saltzman, Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol. Pharm. 6, 173 ( 2009).
22. A. Besheer, J. Vogel, D. Glanz, J. Kressler, T. Groth, and K. Mäder, Characterization of PLGA nanospheres stabilized with amphiphilic polymers: Hydrophobically modified hydroxyethyl starch versus pluronics. Mol. Pharm. 6, 407 (2009).
23. S. Kawa, H. Matsushita, H. Ohbayashi, K. Semba, and T. Yamamoto, A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth. Biochem. Biophys. Res. Commun. 384, 329 (2009).
24. B. Sun, B. Ranganathan, and S.-S. Feng, Multifunctional poly(D,Llactide- co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29, 475 (2008).
25. T. Shishido, H. Mieda, S. Y. Hwang, Y. Nishimura, T. Tanaka, C. Ogino, H. Fukuda, and A. Kondo, Affibody-displaying bionanocapsules for specific drug delivery to Her2-expressing cancer cells. Bioorg. Med. Chem. Lett. 20, 5726 (2010).
26. D. Yu and M.-C. Hung, Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19, 6115 (2000).
27. D. A. Gianolio, C. Rouleau, W. E. Bauta, D. Lovett, W. R. Cantrell, Jr., A. Recio, III, P. Wolstenholme-Hogg, M. Busch, P. Pan, and J. E. Stefano, Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Cancer Chemother. Pharmacol. 70, 439 (2012).
28. H. I. Petrache, S. Tristram-Nagle, and J. F. Nagle, Fluid phase structure of epc and dmpc bilayers. Chem. Phys. Lipids 95, 83 (1998).
29. R. Koynova, B. Tenchov, L. Wang, and R. C. MacDonald, Hydrophobic moiety of cationic lipids strongly modulates their transfection activity. Mol. Pharm. 6, 951 (2009).
30. Y. Zhou, D. C. Drummond, H. Zou, M. E. Hayes, G. P. Adams, D. B. Kirpotin, and J. D. Marks, Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J. Mol. Biol. 371, 934 (2007).
31. J. Liu, G. E. Weller, B. Zern, P. S. Ayyaswamy, D. M. Eckmann, V. R. Muzykantov, and R. Radhakrishnan, Computational model for nanocarrier binding to endothelium validated using in vivo, in vitro, and atomic force microscopy experiments. Proceedings of the National Academy of Sciences 107, 16530 (2010).
32. R. Kaufmann, P. MÜller, G. Hildenbrand, M. Hausmann, and C. Cremer, Analysis of Her2/neu membrane protein clusters in different types of breast cancer cells using localization microscopy. J. Microsc. 242, 46 (2011).
33. P. Nagy, A. Jenei, A. K. Kirsch, J. Szollosi, S. Damjanovich, and T. M. Jovin, Activation-dependent clustering of the ErbB2 receptor tyrosine kinase detected by scanning near-field optical microscopy. J. Cell. Sci. 112, 1733 (1999).
34. S. Yang, M. A. Raymond-Stintz, W. Ying, J. Zhang, D. S. Lidke, S. L. Steinberg, L. Williams, J. M. Oliver, and B. S. Wilson, Mapping ErbB receptors on breast cancer cell membranes during signal transduction. J. Cell. Sci. 120, 2763 (2007).
35. E. J. Smart, C. Mineo, and R. Anderson, Clustered folate receptors deliver 5-methyltetrahydrofolate to cytoplasm of MA104 cells. J. Cell. Biol. 134, 1169 (1996).
36. A. P. Liu, F. Aguet, G. Danuser, and S. L. Schmid, Local clustering of transferrin receptors promotes clathrin-coated pit initiation. J. Cell. Biol. 191, 1381 (2010).
37. C. Cluzel, F. Saltel, J. Lussi, F. Paulhe, B. A. Imhof, and B. Wehrle- Haller, The mechanisms and dynamics of -v-3 integrin clustering in living cells. J. Cell. Biol. 171, 383 (2005).
38. F. S. Hassane, A. F. Saleh, R. Abes, M. J. Gait, and B. Lebleu, Cell penetrating peptides: Overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci. 67, 715 (2009).
39. F. Duchardt, M. Fotin-Mleczek, H. Schwarz, R. Fischer, and R. Brock, A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 848 (2007).
40. I. Nakase, H. Akita, K. Kogure, A. G. Slund, U. L. Langel, H. Harashima, and S. Futaki, Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc. Chem. Res. 45, 1132 (2011).
41. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan, Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100 (2006).
42. K. Takara, H. Hatakeyama, G. Kibria, N. Ohga, K. Hida, and H. Harashima, Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J. Control. Release 162, 225 (2012).
43. S. D. Conner and S. L. Schmid, Regulated portals of entry into the cell. Nature 422, 37 (2003).
44. K. L. Douglas, Toward development of artificial viruses for gene therapy: A comparative evaluation of viral and non-viral transfection. Biotechnol. Progr. 24, 871 (2008).
45. C. Y. M. Hsu and H. Uludaǧ, Cellular uptake pathways of lipidmodified cationic polymers in gene delivery to primary cells. Biomaterials 33, 7834 (2012).
46. S. Xiang, H. Tong, Q. Shi, J. C. Fernandes, T. Jin, K. Dai, and X. Zhang, Uptake mechanisms of non-viral gene delivery. J. Control. Release 158, 371 (2012).
47. D. Vercauteren, R. E. Vandenbroucke, A. T. Jones, J. Rejman, J. Demeester, S. C. De Smedt, N. N. Sanders, and K. Braeckmans, The use of inhibitors to study endocytic pathways of gene carriers: Optimization and pitfalls. Mol. Ther. 18, 561 (2009).
48. J. Rejman, M. Conese, and D. Hoekstra, Gene transfer by means of lipo- and polyplexes: Role of clathrin and caveolae-mediated endocytosis. J. Liposome Res. 16, 237 (2006).
49. L. Zhang, J. M. Chan, F. X. Gu, J.-W. Rhee, A. Z. Wang, A. F. Radovic-Moreno, F. Alexis, R. Langer, and O. C. Farokhzad, Selfassembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. Acs Nano 2, 1696 (2008).
50. J. M. Chan, L. Zhang, K. P. Yuet, G. Liao, J.-W. Rhee, R. Langer, and O. C. Farokhzad, PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30, 1627 (2009).
51. H. Li, T. Luo, R. Sheng, J. Sun, Z. Wang, and A. Cao, Endoplasmic reticulum localization of poly(-aminohexyl methacrylamide)s conjugated with (L-)-arginines in plasmid DNA delivery. Biomaterials 34, 7923 (2013).